UNLOCKING
THE SCIENCE OF
HEALTHIER PETS
UNLOCKING
THE SCIENCE OF
HEALTHIER PETS
THERAPEUTIC POTENTIAL OF HEMP-DERIVED CANNABINOIDS
With CBD being the most abundant cannabinoid extracted from the hemp plant, it is the most studied in terms of its effects on a number of canine conditions including:
- Osteoarthritis pain
- Anxiety
- Allergic/atopic dermatitis
- Refractory seizure control
There are a multitude of receptors involved in the transmission of pain and the perception of pain from the brain that are influenced by hemp derived cannabinoids. The primary cannabinoid extracted from hemp derived Cannabis is distinctly CBD and is the most well documented cannabinoid in both preclinical rodent models and humans due its abundance in hemp. Many of the receptor systems defined within the endocannabinoidome interact with CBD in an antagonistic or agonistic way to influence neuronal excitation or inflammatory pathways.
Absorption of CBDA
is superior to that of
CBD by 4 fold.
THE ACIDIC FORMS OF CANNABINOIDS
In the canine, there are numerous pilot studies using hemp derived isolates of CBD. For many years it was proposed that CBDA was metabolized into CBD within the gastrointestinal tract due the acidic environment, hence they were sometimes considered synonymous.
Innovative research in dogs debunks this bioconversion to CBD theory whereby CBDA is shown to be absorbed quite well in dogs and cats. CBD and CBDA have similar pharmacokinetics, and effective dosing of CBDA shows similar if not higher maximal absorption concentrations over time. Moreover, when comparing absorption of CBD from other studies in dogs at doses similar to those used in Tevelle, the results show superior absorption of CBD when CBDA is present.
The area of acidic forms of cannabinoids is a very exciting field that is currently being explored in the pre-clinical literature. It is not well recognized that the native form of cannabinoids produced in hemp are carboxylic acid derived cannabinoids, primarily CBDA. Prior literature suggested decarboxylation of CBDA into CBD was a common event that occurred with heat, acidic environments, and exposure to UV light, so much so, that research led to synthesis of methyl esters for stabilization of the molecule. However, research by Tevelle shows that CBDA is stable in the appropriate extract for extended periods of time regardless of mild heating and light exposure. These findings open the door to all the acidic forms of cannabinoids for further investigation, which is in its infancy.
The acidic forms of cannabinoids inhibit cyclooxygenase enzymes similar to tradition non-steroidal anti-inflammatory drugs utilized for pain and inflammation. These findings support the use of specific blends of hemp derived cannabinoids for pain and inflammation.
WHY TEVELLE PHARMACEUTICALS
TevElle is pursuing a more effective, safe and environmentally conscious alternative to traditional pharmaceutical products used to treat pets. With a market size of more than $4 billion, there is a significant opportunity to improve the health of pets across a number of addressable conditions through the use of hemp-derived cannabinoids, including their acidic forms.
TevElle Pharmaceuticals ©2023